Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]
News [1431]
Articles [66]
Editorials [2]
Conferences [72]
elearning [5]
A biological perspective for personalising immunotherapies
Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK
A biological perspective for personalising immunotherapies ( Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK )
6 Dec 2017
Editor's Choice for November 2017
Prof Gordon McVie - Founding Editor, ecancer
Editor's Choice for November 2017 ( Prof Gordon McVie - Founding Editor, ecancer )
4 Dec 2017
The promise of immunotherapy for elderly patients
Dr Alistair Greystoke - Newcastle University, Newcastle, UK
The promise of immunotherapy for elderly patients ( Dr Alistair Greystoke - Newcastle University, Newcastle, UK )
15 Nov 2017
Adoptive cell therapy for solid tumours
Dr Sophie Papa - Guy's Hospital, London, UK
Adoptive cell therapy for solid tumours ( Dr Sophie Papa - Guy's Hospital, London, UK )
18 Oct 2017
BRIM8: Vemurafenib in high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
BRIM8: Vemurafenib in high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Expert commentary on melanoma immunotherapy latest
Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard
Expert commentary on melanoma immunotherapy latest ( Dr Jeffrey Weber, Dr Axel Hauschild, Dr Dummer Reinhard )
11 Sep 2017
Vemurafenib for high risk melanoma patients
Dr Karl Lewis - University of Colorado Denver, Colorado, USA
Vemurafenib for high risk melanoma patients ( Dr Karl Lewis - University of Colorado Denver, Colorado, USA )
11 Sep 2017
Dabrafenib plus trametinib for stage III mutant melanoma
Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
Dabrafenib plus trametinib for stage III mutant melanoma ( Dr Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )
11 Sep 2017
Nivolumab vs ipilimumab for high risk melanoma patients
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Nivolumab vs ipilimumab for high risk melanoma patients ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection ( Dr Jeffrey Weber - Perlmutter Cancer Center, New York, USA )
11 Sep 2017
The METRIC trial of trametinib, five years on
Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany
The METRIC trial of trametinib, five years on ( Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany )
10 Sep 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation